Markus Sieger has been actively involved in public and private pharmaceutical companies since over 20 years. He has been actively advising entrepreneurs in the healthcare space, negotiated joint-ventures between global pharmaceutical groups and local champions and served on both public and private boards of pharma companies. Recently he was nominated CEO of a large pharmaceutical generics group also active in Biosimilars. Furthermore he is a key investor and lead director in a public orphan drug development company.
Board of Directors
Markus SiegerMember board of directors
Werner KormelinkMember board of directors
Werner Kormelink has more than 20 year of experience as in-house tax director, advisor and management of holding & finance entities with privately owned businesses and multinationals in Western and Eastern Europe, Israel, US and Japan, including large pharmaceutical companies. Actively involved in management of effective tax rates, management of risks and reputation, change management, M&A, divestments, corporate restructuring and transactions, BEPS and transfer pricing, treasury transactions, tax audits and WHT issues. He is dedicated open-minded, down to earth, a true team builder and team player, and he has a great sense of humour.